Two new "super Gleevec" drugs are nearing the market--dasatinib from Bristol-Myers Squibb and nilotinib from Novartis.

FORBES: Magazine Article

Dasatinib can gum up the protein when the flap is open or closed.

FORBES: The Race Is On

Then he heard about an experimental drug called dasatinib being tested at UCLA's Jonsson Cancer Center, near his Lakewood, Calif. home.

FORBES: Magazine Article

Two new "super Gleevec" drugs are nearing the market--dasatinib from Bristol-Myers Squibb (nyse: BMY - news - people ) and nilotinib from Novartis.

FORBES: The Race Is On

Bristol-Myers originally designed dasatinib to block a mutant protein in other tumors, but in 2001 company pharmacologist Francis Lee noticed that it was hundreds of times more potent than Gleevec in blocking the CML cell growth.

FORBES: The Race Is On